Kura Oncology, Inc. (KURA)
NASDAQ: KURA · Real-Time Price · USD
6.49
-0.07 (-1.14%)
May 1, 2025, 4:00 PM EDT - Market closed

Company Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors.

It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.

The company is headquartered in San Diego, California.

Kura Oncology, Inc.
Kura Oncology logo
Country United States
Founded 2014
Industry Biotechnology
Sector Healthcare
Employees 192
CEO Troy Wilson

Contact Details

Address:
12730 High Bluff Drive, Suite 400
San Diego, California 92130
United States
Phone 858 500 8800
Website kuraoncology.com

Stock Details

Ticker Symbol KURA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001422143
CUSIP Number 50127T109
ISIN Number US50127T1097
Employer ID 61-1547851
SIC Code 2834

Key Executives

Name Position
Dr. Troy Edward Wilson J.D., Ph.D. Chairman, Chief Executive Officer and President
Kathleen Ford Chief Operating Officer
Teresa Brophy Bair Esq., J.D. Chief Legal Officer and Corporate Secretary
Thomas Doyle Senior Vice President of Finance and Accounting
Dr. Francis J. Burrows Ph.D. Chief Scientific Officer
Dr. Roger Bakale Ph.D. Senior Vice President of Manufacturing and Supply Chain
Maureen Clancy M.B.A. Vice President and Global Head of Program Leadership and Project Management
Dr. Mollie Leoni M.D. Chief Medical Officer
Brian T. Powl M.B.A., M.S. Chief Commercial Officer

Latest SEC Filings

Date Type Title
May 1, 2025 10-Q Quarterly Report
May 1, 2025 8-K Current Report
Apr 17, 2025 ARS Filing
Apr 17, 2025 SCHEDULE 13G/A Filing
Apr 11, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 11, 2025 DEF 14A Other definitive proxy statements
Mar 21, 2025 144 Filing
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 28, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report